acib

WHERE INNOVATION STARTS

MEET THE START-UPS AND SPIN-OFFS OF ACIB



FUNDED BY



 Bundesministerium Klimaschutz, Umwelt, Energie, Mobilität, Innovation und Technologie











Content

bisy e.U.	06
Chorus GmbH	08
DirectSens GmbH	10
Enzyan Biocatalysis GmbH	12
Evercyte GmbH	14
Innophore GmbH	16
Qualizyme Biotechnology GesmbH	18
roombiotic GmbH	20
Syconium Lactic Acid GmbH	22
CelHeal	24
myBIOS GmbH	26
econutri GmbH	28
agrobiogel GmbH	30
Arkeon GmbH	32
KS KETONUTRIENTS GmbH	34
Lanbiotic GmbH	36

Innovation Incubator and Spin-Off Center

As innovation incubator the Austrian Centre of Industrial Biotechnology (acib) accompanies its spin-offs, start-ups and center-related companies on their first steps towards business success. acib offers tailor-made services, substantial know-how and access to an extensive network of industrial and academic partners.

You are a scientist and have a splendid idea?

We can help you to make your know-how ready for the market. You think the first steps towards entrepreneurship are tricky? We can accompany you on your route towards your own start-up company.

If you already have founded a company, we can help you to gain added value for your business through a broad spectrum of hand-picked measures. Our access to most recent research results of the acib network partners makes entering the market or even breaking into new markets easier and less complicated. Thus, our spin-offs and start-ups benefit from first-hand international expertise and can better focus on day-to-day business.

The following companies – from all fields of industrial biotechnology – give an overview of our accomplishments and are examples for a successful cooperation with future industries.





bisy e.U.

THE STORY

Prof. Anton Glieder took a sabbatical from his position as CEO / CSO of acib to spend an extended period of time in the "Biotech Valley" in San Diego to brainstorm and collect new ideas. Inspired by the innovative research environment made up by more than 400 companies, Anton was able to establish vital new contacts with industrial enterprises, and he caught the "entrepreneurial bug". Back in Graz, he leveraged the comprehensive expertise of acib and Graz University of Technology and used it as a stepping stone to establish a spin-off company dedicated to "translating" patents and research achievements into concrete products, direct contract research projects and services for enterprises. This was not the only motivation for Anton to set up his business, however, he was also determined to strengthen Graz as a place of biotechnology research and develop new areas of application for life sciences.

ABOUT THE COMPANY

Biochemistry needs tools to produce medication, hygiene articles and materials. The spin-off from acib and Graz University of Technology provides these molecular tools to all areas of industrial biotechnology. The raw materials in this case are enzymes that are "adjusted" for specific tasks by means of bioengineering. bisy intends to create a bridge between applied research and productive industry so that users will in future be able to develop more efficient tools and processes that are gentle on the environment for the manufacture of sustainable products. Customers from research and industry include the animal feed, textile or paper industries, waste water management, pharmaceutical and come from Europe, Asia and the USA.

>>> The foundations for many of our ideas have been laid in acib and are now industrially applied by bisy. Being a network center acib bundles comprehensive expertise and is flexible enough to create and support innovative solutions.



Founding year	2014
Connected with acib	since 2014
Locations	Graz, Gleisdorf
Employees	7
Industry sectors	Industrial biotechnology
Managing director	Anton Glieder

What we do

Development of molecular and enzymatic tools for the biochemical industry for the production of pharmaceutical, agricultural or biochemical products.

5152

Chorus GmbH

THE STORY

CHO-host systems are presently the most essential production system for the production of biopharmaceutical agents. A strong general drive to bring down production costs and continuously improve the quality of products is found everywhere in industry today. Chorus works on optimising these two key objectives. The spin-off Chorus was established in 2011 starting from research achievements of the University of Natural Resources and Life Sciences, Vienna in the area of CHO cells that were further developed at acib. Cooperation with acib began in 2012. acib scientist Prof. Nicole Borth provided vital input for the development of the strategy of Chorus.

ABOUT THE COMPANY

Chorus develops new CHO-host systems for the production of biopharmaceutical agents (CyberSpeed Cell Platform), and to this end compares the sequences of the genome of the Chinese hamster and a variety of industrially used CHO-host systems. Significant have been discovered (which can be exploited for industrial needs.) The aim is now to modify genes that are responsible for growth and genetic stability to generate better CHO host systems. The highly developed genome sequence data platform that is based on CHO cell lines and the comprehensive expertise of acib in this field of research are essential parameters for the development of our CyberSpeed Cell platform.

>>> acib's highly developed genome sequence platform based on CHO cell lines and the extensive know-how in this field are important factors for the development of our CyberSpeed Cell Platform. <



Founding year	2011
Connected with acib	since 2012
Locations	Böheimkirchen
Employees	1
Industry sectors	Biotechnology
Managing director	Otto Kanzler

What we do

Chorus develops new CHO-host systems for the production of biopharmaceutical agents.



DirectSens GmbH

THE STORY

DirectSens GmbH was established to put the research findings of its founders Roland Ludwig, Wolfgang Harreither, Christoph Sygmund, Roman Kittl and Alfons Felice to commercial use. The shareholders have always attached great importance to translating research into something tangible, into a useful product. Starting from a patent of researchers of the Vienna University of Natural Resources and Life Sciences, Lund University and acib, the biosensor development was launched in 2009 with financial support from tecnet. The company was established in 2013 in the framework of a PreSeed funding scheme of Accent and AWS. The corporate capital was increased by private investors in 2015.

ABOUT THE COMPANY

Within 18 months from the establishment of DirectSens GmbH, the company developed a biosensor for the detection of minimum lactose concentrations in lactose-reduced dairy products from prototypes. The biosensor has been marketed globally by Chr. Hansen (Denmark) since 2016. In addition to the further development of this product, the research team also works on glucose sensors for blood glucose monitoring and other new biosensors for application in food analysis and biotechnology. DirectSens cooperates most efficiently and across disciplines with university and industrial cooperation partners to develop new biosensors with market potential.

>>> acib's focus on industrial research taught us to always consider the applicability of a new development, to detect new fields of application and to assess the market potential. This, combined with the extensive acib network, is an invaluable asset. <<



Founding year	2013
Connected with acib	since 2009
Locations	Klosterneuburg, Vienna
Employees	10
Industry sectors	Food analysis
Managing directors	Christoph Sygmund Roman Kittl Alfons Felice Wolfgang Harreither Roland Ludwig

What we do

Development of 3rd generation biosensors for food analysis and medical applications



10

Enzyan Biocatalysis GmbH

THE STORY

Enzyan Biocatalysis acts as a contract research organization and was founded in spring 2022 by Stefan Payer, Mathias Pickl-Farnberger, Elisa Lanfranchi, Mattia Lazzarotto, and Wolfgang Kroutil as a joint spin-off company of the University of Graz and acib GmbH. The company is currently located at the campus of the University of Graz, where it receives strong support from the Unicorn entrepreneurship center.

ABOUT THE COMPANY

Enzyan Biocatalysis aims to provide industrial partners the tools for the implementation of green and more economic biomanufacturing processes for (fine) chemicals/pharmaceuticals. This is achieved by the identification, development and optimization of potentially more efficient and sustainable synthetic routes. We use a broad set of tools to test the production of biocatalysts in *Escherichia coli* and characterize enzymes in view of their biocatalytic properties. We design biocatalytic routes and enzymatic cascades and identify the optimal process parameters by combining a highly automated and integrated wet-lab infrastructure, professional personnel and cutting-edge computational tools. The expertise in solving challenging problems at the interface of synthetic chemistry and enzymatic transformations is considered the core strength of the company.

>>> Our strong bond with acib GmbH and the University of Graz allows us to be on the forefront of new innovations in an extremely know-how dependent field. Many ideas were triggered in this framework and the expertise in acib enables further exploration.



Founding year	2022
Connected with acib	2022
Locations	Graz
Employees	5
Industry sectors	Biotechnology
Managing directors	Stefan Payer

What we do

Developing economic protocols of sustainable multi-step biocatalytic processes for pharmaceuticals and (fine) chemicals.

Evercyte GmbH

THE STORY

Evercyte GmbH was founded in 2011 as a spin-off of the Institute for Applied Microbiology of University of Natural Resources and Life Sciences, Vienna by Prof. Regina Grillari (CTO), Prof. Johannes Grillari (CSO) and Otto Kanzler (CEO). The business concept is based on the scientific findings of Prof. Regina Grillari in the field of the development of human cells as alternative test models for the pharmaceutical, chemical and cosmetic industries, and the findings of Prof. Johannes Grillari in the research of regulatory mechanisms of cell ageing. Prof. Regina Grillari and Prof. Johannes Grillari also work at the University of Natural Resources and Life Sciences, Vienna (BOKU) and are involved in various acib projects.

ABOUT THE COMPANY

Evercyte develops and markets immortalised human cell lines and/or induced pluripotent stem cells (iPS) derived from human urine, plus the respective cell culture media. In addition, Evercyte also acts as a contract research organisation and carries out development projects tailored to customer demands. These projects can be accomplished using both established cell lines (cell-based assay development, for example) or with new, immortalized cell lines. Depending on customer demands, new immortalized cell lines can also be ordered (customer tailored cell line services). The company sees its strengths in the development and reliable implementation of new technologies and specialised research contracts.

>> Being an international competence center in industrial biotechnology acib offers important scientific incentives for many of our applications and products. 巜



Founding year	2011
Connected with acib	since 2011
Locations	Vienna
Employees	6
Industry sectors	Biotechnology
Managing directors	Otto Kanzler, CEO Regina Grillari, CTO Johannes Grillari, CSO

What we do

- · Research & development cell biotechnology
- Marketing of immortalised human cell lines and/or induced, pluripotent stem cells (iPS)
- · Marketing of cell culture media and cell culture components
- · Contract research



Innophore GmbH

THE STORY

- acib and Graz University developed the basic concept in 2012 (patent application/inventor registration)
- Science Park foundation project 2015
- Investor pitching SFG Performance99 Q4 2016
- · Investor negotiations with EOSS Industries Q1-Q2 2017
- Pilot phase establishment of Innophore GmbH with investor support in 2017

ABOUT THE COMPANY

"Enzyme-Google" was developed in the course of a research project of the Austrian Centre of Industrial Biotechnology GmbH and makes possible the search for enzymes in a dedicated new database. The bio-tech start-up company Innophore, a spin-off of acib and University Graz, commercialises this technology. Innophore aims to establish this new method on the market to identify and predict enzymatic activities based on the three-dimensional structure of proteins. By this means both new enzymes for industrial biocatalysis and alternative enzymes for medical applications are to be identified.

>>> As a spin-off company from the Austrian Centre of Industrial Biotechnology and the University of Graz we are embedded in a highly active academic and industrial network covering more than 100 national and international partners in the field of biotechnology.



Founding year2016Connected with acibsince 2015LocationsGrazEmployees3Industry sectorsBiotechnologyManaging directorsChristian Gruber
Georg Steinkellner
Christoph Blaschitz

What we do

Innophore uses computer algorithms for identifying enzyme alternatives to existing or new processes in the pharmaceutical and chemical industries. Innophore looks for specific enzymes that have no similarity with enzymes used so far, either in terms of their structure or the sequential basis.



Qualizyme Biotechnology GesmbH

THE STORY

The issue of wound infections first triggered the interest of Dr. Eva Sigl and Dr. Andrea Heinzle, both former acib employees, in the framework of the "Lidwine" EU project (2006-2010) dedicated to wound healing, and the two scientists started researching this field. Convincing data were soon generated (in 2008); and in 2009 the first patent on detection of wound infection was filed, followed by the publication of data. The "InFact" project in which acib was one of the partners was launched after their victory in the Ideas Competition 2008, organized by the Science Park Graz and received aws PreSeed funding. Experienced businessman and entrepreneur Dr. Michael Burnet joined the team, and in 2014, the company rented a laboratory and office in ZWT Graz. In 2016, Qualizyme received core funding from the Austrian Research Promotion Agency (FFG). At the end of 2017, a production line including clean room for the production of biochemical substrates was completed, which are part of the quick test developed for the detection of infections.

ABOUT THE COMPANY

Qualizyme Diagnostics is a high-tech start-up company offering point-of-care infection diagnosis (POCT). A quick test for simple and reliable identification of wound infections was developed and will have a roll-out in various models. Besides the focus on R&D and the development of technology, we have been working on establishing our own production site for the biochemical substrates we develop. This process was concluded with the set-up of a clean room at the end of 2017. Qualizyme has been company partner of acids since 2011 and appreciates the good infrastructure and the exchange with its competent colleagues and heads of department.

>>> Qualizyme has been a company partner of acib since 2011 and appreciates the good infrastructure and the scientific exchange with competent contact persons and area leaders.



Founding year	2015
Connected with acib	since 2011
Locations	Graz
Employees	6
Industry sectors	Medical technology
Managing directors	Andrea Heinzle Eva Sigl Michael Burnet

What we do

Qualizyme has many years of experience in enzyme kinetics, enzyme production and protein expression. Enzyme assays are developed for various applications (mainly in the field of medical diagnostics) and enzyme substrates are developed and produced.



roombiotic GmbH

THE STORY

The company was founded in 2014 and emerged from a joint research project of Graz University of Technology and RCPE (Research Center Pharmaceutical Engineering). The original research project discovered beneficial microorganisms on the Styrian oil pumpkin that may counteract pathogens leading to crop failure. Oil pumpkins use these natural microorganisms to protect themselves from rotting. Bioactive substances that are produced by these microorganisms were then transferred to industrial processes.

ABOUT THE COMPANY

roombiotic produces tailored formulations for food production, feed production and health care. Selected biogenic substances are developed jointly with the customers to meet their specific applications. These substances can act as natural disinfection agents for surfaces and food. roombiotic currently achieves highly effective germ control in all areas. In combination with the appropriate dosage equipment, the agent is precisely applied and thus ensures permanently sanitised production environment. Depending on the area of application (e.g. bakeries), roombiotic determined the necessary concentration and composition required to optimise the sensory influence while maximising the efficacy at the same time.

Fundamental knowledge of the mode of action for specific bioactive substances was developed within a cooperation scheme with acib.

>>> Within a cooperation with acib fundamental insights in the active principles of certain bio-active substances could have gained.



Founding year	2014
Connected with acib	since 2015
Locations	Graz, Gleisdorf
Employees	3
Industry sectors	Biotechnology
Managing directors	Daniel Treffer

What we do

roombiotic develops processes for sustainable use of biogenic agents for germ control. The applications aim to reduce pathogens on the surface of food and feedstuff, equipment, machinery and plant.



Syconium Lactic Acid GmbH

THE STORY

The founders of Syconium Lactic Acid (SLA) wanted to develop innovative solutions to reduce the global problem of plastics by means of recombinant microorganisms. After funding had been secured, SLA was founded in 2014 and the research and development work began. Transform Science Management & Consulting GmbH, a former spin-off company of Boehringer and project partner, was merged into SLA. The acib scientists Prof. Diethard Mattanovich and Dr. Michael Sauer made vital contributions to drawing up SLA's corporate concept.

ABOUT THE COMPANY

SLA has set itself the goal of producing lactic acid in a cost-efficient manner and to provide a building block for the production of biodegradable plastic made out of poly-lactic-acid (PLA). The plan is to license the technology to globally acting companies when the development has been completed (2019).

>>> Knowledge transfer, innovative research and most recent know-how in the fields of metabolic and bioprocess engineering are common denominators of SLA GmbH and acib. We are proud to have acib as an important partner on our side.



Founding year	2014
Connected with acib	since 2015
Locations	Vienna
Employees	2
Industry sectors	Biotechnology
Managing director	Otto Kanzler

What we do

Development of a new cost-efficient method for the production of D and L-lactic acid.



CelHeal

THE STORY

The poly(oligo)saccharides present in the cell-wall become the "front line troops" during the early phase of infection, trigger the cascade of cellular reactions in host cells, and thus, in turn, will activate the whole defense mechanism of the host. Despite their essential role in immune modulation, these most valuable biomolecules have not gained recognition as an active ingredient in industrial applications due to their structural complexity and difficulty in *in-vitro* synthesis in their pure form. CellHeal is founded to overcome these challenges. The business concepts of CellHeal have been formulated based on the scientific experience gained from research activities in collaboration with TU Graz and the information gathered from the primary market research while working at acib GmbH

ABOUT THE COMPANY

The goal of our business is to identify and enzymatically synthesize the welldefined cell-wall poly(oligo)saccharides that can act as immunomodulators. To achieve this, we carefully understand the enzymatic reactions occurring at a cellular level, produce these enzymes in the laboratory and employ them to synthesize such polysaccharide products embracing sustainability and greenfriendly practices. The conventional chemical process cannot synthesize these well-defined polysaccharides because of several stereochemical issues, and the chemical processes are often destructive in nature. These well-defined poly(oligo)saccharides are used in health (human, animal, and plant) and beauty applications.

>>> Being an international competence center for industrial biotechnology, in addition to providing a superior work environment to advance your scientific career, acib offers a distinguished learning platform to help you hone your entrepreneurial skills and prepare for the entrepreneur life you want. <<



Founding year	2017	What we do
Connected with acib	2012	We produce poly(oligo)saccharides and their derivatives that are used in health
Locations	Graz	(human, animal and plant) and beauty applications.
Employees	1	
Field(s) covered	Health and Beauty applications	
Managing director	Rama Krishna Gudiminchi	

myBIOS GmbH

THE STORY

bisy BIOS GmbH is a spin-off of bisy GmbH and acib GmbH. bisy BIOS was founded in 2020 by Claudia Rinnofner. The company focuses on self-produced antigens and novel strategies for antibody testing. The headquarters are located in Hart near Graz. As of September 2021, the company has moved into its new laboratory at the ZWT (Centre for Knowledge and Technology Transfer in Medicine, Neue Stiftingtalstraße 2, 8010 Graz). The search for investors and co-founders is currently at the forefront.

History of origins

- · Basic idea 2020 still at bisy
- myBIOS GmbH Foundation November 2020
- Science Park Ideas Competition winner in the Health category (April 2021)
- · Science Park incubation since July 2021

ABOUT THE COMPANY

We focus on the production of proteins with yeast. Recombinant protein production enables us to develop smart materials and catalysts. Due to the exceptional situation COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 with over 2 million deaths, our first product is the SARS-CoV-2 spike protein and variants thereof. Our spike proteins can be used in diagnostic antibody tests and possibly even as the basis for vaccine development. In addition to antigens, we will also devote special attention to therapeutic proteins such as antimicrobial proteins/peptides in the future.

>>> We believe that proteins are the key to some of society's biggest challenges <<



	Founding year	2020
	Connected with acib	2021
	Locations	Graz
	Employees	1
	Field(s) covered	Biotechnology
	Managing director	Claudia Rinnofner

What we do

We enable rapid diagnostics and vaccine development by producing proteins safely, ecologically and sustainably with yeast.

myBIOS

Econutri GmbH

THE STORY

The idea of producing protein from CO_2 has a long history in Graz. As early as the 1970s, Helmut Schwab conducted the first molecular genetic research on the bacterium *Cupriavidus necator*, which can grow with CO_2 as a nutrient source, as part of his dissertation. However, the topic of CO_2 did not have a broad echo 50 years ago. The extreme increase in CO_2 pollution of the environment in the 21st century has now made this topic topical. Helmut Schwab took the initiative and continued the research work started at the TU Graz and at acib. With partner Stefan Zopf, the financial and technological basis was laid to enter the direct development of production processes with a strong concept and the competent team of Econutri.

ABOUT THE COMPANY

Econutri GmbH builds on the expertise developed at TU Graz and acib with the chemolithoautotrophic bacterium *Cupriavidus necator*. The company was founded to develop efficient and commercially viable processes for the production of protein from CO_2 with a strong base and innovative concepts. Econutri makes a significant contribution to cycling CO_2 while saving resources of cultivable land and fish stocks.



Founding year	2021
Connected with acib	2021
Locations	Graz
Employees	3
Field(s) covered	Biotechnology
Managing director	Verena Schwab

What we do

Econutri develops production processes to produce protein for the food supply of animals and humans on the basis of CO₂



Agrobiogel GmbH

THE STORY

Agrobiogel GmbH is a spin-off from the University of Natural Resources and Life Sciences, Vienna (BOKU) working on establishing its industrial production process of lignin hydrogels, which are being used in an agricultural application for the first time. This innovative technology stems from an idea by co-founder and lead inventor Dr. Gibson S. Nyanhongo and his team and and a patent has been filed.

Hydrogels – also known as superabsorbents – are polymeric materials able to absorb and store huge amounts of water. When applied to the soil, they act as small water and nutrient reservoirs right at the roots of the plants. Based on these properties, Agrobiogel helps farmers, plant- and forest growers etc. in both rural and urban centers to (1) save agrochemicals and reduce input costs, (2) save irrigation water by reducing the irrigation frequency (produce more with less water) and (3) also to protect crops, trees and plants from droughts during the absence of rain over extended time periods.

ABOUT THE COMPANY

Agrobiogel GmbH produces watersuper absorbent products for agriculture applications. The major aim of Agrobiogel is to help farmers and plant- or forest growers etc. in both rural and urban centers to save water and protect crops, trees and plants from droughts.

>> In relationship with BOKU and acib, Agrobiogel is investigating the impact of enzymatically polymerized lignin on improving soil properties, soil microbial ecosystem and supporting plant growth and health. <<



Founding year	2021
Connected with acib	February 2021
Locations	Tulln an der Dona
Employees	6
Field(s) covered	Agriculture
Managing director	Johannes Paul Schwarz

What we do

We produce watersuper absorbent products for agriculture applications.



Arkeon GmbH

THE STORY

The origins of Arkeon stem from a collaboration between co-founders Simon Rittmann (University of Vienna) and Günther Bochmann (BOKU), in which research was conducted on novel production methods of value added compounds by gas fermentation. Within the project a new biosynthetic production pathway for proteinogenic substances in archaea was discovered. With the support of ACIB, a network to Gregor Tegl and founding investors was established, which provided the impetus for the successful foundation of Arkeon.

ABOUT THE COMPANY

Arkeon is developing the most sustainable way to produce food. The company uses archaea to produce the purest and most complete protein from the CO2 in our atmosphere. In doing so, the founders are dedicated to changing the food system as we know it and have found ways to produce protein without agricultural inputs. Arkeon's mission is to use the power of microbes to mitigate the environmental impact of our food system and to increase food security.

 $>\!\!>$ acib has provided a holistic network and support that has enabled us to create Arkeon in the current form. $<\!\!<$



Founding year	2021
Connected with acib	2021
Locations	Tulln an der Donau
Employees	5
Field(s) covered	FoodTech
Managing director	Gregor Tegl

What we do

Arkeon develops sustainable technologies for the fermentative production of food and additives from CO_2 - without resource constraints, geographical limitations and free from animal suffering.



KS KETONUTRIENTS GmbH

THE STORY

The company was founded in 2023 and emerged from a joint research work together with the University of Technology Graz and acib GmbH. The aim of this research was to develop efficient enzymes for the degradation of polyhydroxyalkanoates (PHA). It was possible to find a very efficient enzyme. Furthermore, in parallel research work carried out in the company Molekulare Biotechnologie e.U., investigations were carried out to develop PHA-based scaffolds for the cultivation of mammalian cells. These results finally gave the impetus to found a company for further development.

ABOUT THE COMPANY

KETONUTRIENTS develops enzymes for the efficient degradation of PHAs. These enzymes are used to produce controlled degradable PHA based polymer products. By suitably combining the enzymes with the polymer matrix, tailor-made polymer structures are produced that are degraded over defined periods of time. Such structures are of interest as scaffolds for the cultivation of mammalian cells. Cells grow on this matrix, and at the same time this matrix is degraded by the enzymes in a controlled manner. Since the degradation products of PHAs, especially polyhydroxybutyrate (3-hydroxybutyrate) are natural metabolites in mammalian cells, they are fully biocompatible. Areas of application for these controlled degradable polymer structures are in medical research and applications. Other areas of interest include the *in vitro* production of "artificial meat".

>>> Within a cooperation with acib, important fundamentals for the production of targeted enzymatically degradable structures from PHA could be established. <



Founding year	2023
Connected with acib	2021
Locations	Graz
Employees	1
Field(s) covered	Biotechnology
Managing director	Dr. Christoph Reisinger

What we do

KETONUTRIENTS develops products for the sustainable use of degradable biopolymers whose monomers are natural metabolites of cells. The focus of the applications lies in the fields of medicine and alternative food.



Lanbiotic GmbH

THE STORY

Lanbiotic was founded by Dr. Katrin Susanna Wallner and Patrick Hart. The idea grew out of Dr. Wallner's clinical experience as a dentist and her interest in the importance of a balanced microbial ecosystem for human health. As part of her research on the skin microbiome, she discovered a new strain of bacteria that inhibits the growth of S. aureus, a bacterium associated with the development of atopic dermatitis. Together with the patent-pending encapsulation technology that allows the products to be stored, the foundation was laid for the creation of Lanbiotic and the development of a wide range of new products.

ABOUT THE COMPANY

Lanbiotic GmbH is an innovative company based in Graz, Austria, focused on the characterization and cell encapsulation of new probiotic strains.By using and patenting an innovative encapsulation technology, the company is able to bring a wide range of products to the market. To ensure maximum quality and impact of developments, the company works closely with leading scientists and research institutions and strives to fully exploit the potential of probiotic products to improve skin health.Lanbiotic is currently incubated in the Science Park Graz and is supported by public funding, including the FFG-Basis program and aws Preseed.

 \gg acib is an indispensable partner for us. The people involved stand out for their exceptional competence and commitment. \ll



Founding year	2022
Connected with acib	2021
Locations	Graz
Employees	2
Field(s) covered	Medicine, Cosmetics
Managing director	Dr. Katrin S. Wallner

What we do

Lanbiotic focuses on the development and distribution of probiotic formulations for medical and cosmetic applications.



The Austrian Centre of Industrial Biotechnology

ABOUT ACIB

The Austrian Centre of Industrial Biotechnology (acib) is a top-class international research institution in the field of industrial biotechnology. Since its foundation in 2010 the center of excellence has specialized on the development of innovative, eco-friendly and economical processes for the biotech-, chemical- and pharmaceutical industries using the methods and tools of nature. Presently 200+ coworkers are carrying out research in more than 175 research projects.

OUR RESEARCH DOMAINS

acib carries out research in all field of industrial biotechnology. Its extensive expertise covers 12 research fields from biocatalysis and recombinant protein production to modelling and engineering and bioprocessing.

OUR NETWORK

The non-profit organization with its headquarters in Graz has additional sites in Innsbruck, Tulln, Vienna, Linz (AUT), Bielefeld, Heidelberg and Hamburg (GER), Pavia (ITA), Barcelona (ESP), Rzeszów (POL), Canterbury (NZL) and Hsinchu (TWN) and bundles a consortium of 200 academic and industrial partners. Among the partners are renowned companies such as BASF, DSM, Sandoz, Boehringer Ingelheim RCV, Jungbunzlauer and VTU Technology.



Watch our **blog** & listen to our **podcast** at www.acib.at/news

acib GmbH Krenngasse 37 8010 Graz

- +43 316 873 9316
- ➡ bd@acib.at
- www.acib.at



www.acib.at